Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 May 2022
TGA removes age limit for BBIBP-CorV (Sinopharm) COVID-19 vaccine recognition for international travel to Australia
13 May 2022 - The TGA has determined that the BBIBP-CorV (Sinopharm) COVID-19 vaccine will be 'recognised' for all ages for ...
Posted by Michael Wonder on 12 May 2022
CADTH expands scientific advice program to include advice on real world evidence
28 April 2022 - CADTH is expanding its scientific advice program to include applications for advice on real world evidence generation ...
Posted by Michael Wonder on 12 May 2022
Basket trials: review of current practice and innovations for future trials
10 May 2022 - Basket trials, one type of master protocol, emerged as a tool for evaluating biomarker-targeted therapies among multiple ...
Posted by Michael Wonder on 12 May 2022
Federal investigators find Medicare Advantage plans too often deny, delay needed care
10 May 2022 - Medicare Advantage plans that provide health insurance coverage to millions of US seniors deny some medically ...
Posted by Michael Wonder on 12 May 2022
ATAGI update following weekly COVID-19 meeting (11 May 2022)
12 May 2022 - On Wednesday 11 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 12 May 2022
FDA approves oral formulation of treatment for amyotrophic lateral sclerosis
12 May 2022 - Today, FDA approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis. ...
Posted by Michael Wonder on 12 May 2022
Moderna completes FDA submission for use of COVID shot in adolescents, kids
11 May 2022 - Moderna has made all necessary submissions required by the U.S. FDA for emergency use authorisation of ...
Posted by Michael Wonder on 12 May 2022
After a 5 year fight to lower drug prices, Ottawa's pledge quietly falls apart
12 May 2022 - What began with a promise to protect Canadians ended with a commitment to support pharmaceutical companies. ...
Posted by Michael Wonder on 12 May 2022
FDA grants breakthrough device designation to Remedee Labs for its groundbreaking endorphin stimulation solution for the management of fibromyalgia
12 May 2022 - On World Fibromyalgia Awareness Day (May 12), the French startup Remedee Labs is announcing that the FDA ...
Posted by Michael Wonder on 12 May 2022
Wysa receives FDA breakthrough device designation for AI led mental health conversational agent
12 May 2022 - New peer-reviewed studies demonstrate efficacy in managing chronic pain, depression and anxiety ...
Posted by Michael Wonder on 12 May 2022
COVID-19 vaccine weekly safety report (12 May 2022)
12 May 2022 - To 8 May 2022, the TGA has received 554 reports which have been assessed as likely to ...
Posted by Michael Wonder on 11 May 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
11 May 2022 - NICE has published evidence based recommendations on the use of avelumab for adults with locally advanced ...
Posted by Michael Wonder on 11 May 2022
ATAGI update following weekly COVID-19 meeting (4 May 2022)
9 May 2022 - On Wednesday 4 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 11 May 2022
Amicus Therapeutics receives notification of PDUFA date extensions for AT-GAA
10 May 2022 - Amicus Therapeutics today announced that the U.S. FDA has extended the review period by 90 days ...
Posted by Michael Wonder on 11 May 2022
Remake of the National Health (Pharmaceuticals and Vaccines – Cost Recovery) Regulations 2009
11 May 2022 - The Department has recently remade the National Health (Pharmaceutical and Vaccines—Cost Recovery) Regulations 2009 (2009 Regulations), ...